Brief: Adaptive Biotechnologies Announces Launch Of Clonoseq® To Assess Minimal Residual Disease (Mrd) In Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) Using Circulating Tumor Dna (Ctdna)
01/12/2022 12:31
Dec 1 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES ANNOUNCES LAUNCH OF CLONOSEQ® TO
ASSESS
MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DIFFUSE LARGE
B-CELL LYMPHOMA (DLBCL) USING CIRCULATING TUMOR DNA (CTDNA)
Source text for Eikon: ID:nGNX76RY0k
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile